GLP-1 Insurance Coverage: What Patients and Practices Need to Know

Despite the strong clinical evidence for GLP-1 therapy in obesity and metabolic disease, insurance coverage remains inconsistent, inadequate, and often inaccessible for many patients. Understanding the coverage landscape helps practices counsel patients effectively and explains why compounded GLP-1s remain essential for patient access.

Branded GLP-1 medications for weight management (Wegovy, Zepbound) cost $900–$1,400 per month at retail prices. For most patients, this is unaffordable without insurance coverage.

The coverage situation:

Medicare: Medicare Part D historically excluded coverage for weight loss medications. The Inflation Reduction Act of 2022 did not include GLP-1 coverage for obesity. As of 2026, Medicare coverage for GLP-1s for obesity remains limited, though coverage for cardiovascular risk reduction (following the SELECT trial) has expanded.

Medicaid: Coverage varies dramatically by state. Some states cover GLP-1s for obesity; many do not.

Commercial insurance: Coverage varies by plan. Many commercial plans cover GLP-1s for type 2 diabetes but not for obesity alone. Some plans have added obesity coverage following the SELECT trial cardiovascular outcomes data.

Employer plans: Large self-insured employers have been the most progressive in adding GLP-1 coverage, but many have also added prior authorization requirements and step therapy requirements that create access barriers.

For patients who cannot access branded GLP-1s through insurance, compounded preparations offer a critical access pathway:

Cost: Compounded semaglutide and tirzepatide are significantly less expensive than branded products — often $150–$400 per month depending on dose and supplier.

Availability: Compounded preparations are available without the prior authorization and step therapy requirements that delay access to branded products.

Flexibility: Compounded preparations can be customized to the exact dose and formulation the prescriber determines is appropriate.

For practices, the ability to offer compounded GLP-1s means you can serve patients who would otherwise be unable to access therapy — expanding your patient population and your practice's impact.

For patients who want to pursue insurance coverage for branded GLP-1s, here is what the process typically looks like:

Most insurance plans require prior authorization for GLP-1 medications. The PA process typically requires:

• Documentation of BMI ≥30 (or ≥27 with comorbidity)
• Documentation of prior weight loss attempts
• Clinical notes supporting the prescription
• Sometimes: documentation of specific comorbidities (T2D, cardiovascular disease)

Practice tip: Develop a PA template that includes all required documentation. This reduces the administrative burden and improves approval rates.

Some plans require patients to try and fail less expensive medications before approving GLP-1s. This can delay access by months.

Practice tip: Document any prior weight loss medication trials in the patient record. This documentation is required for step therapy exceptions.

When PA is denied, appeal. Many denials are overturned on appeal, particularly when the prescriber provides a compelling clinical rationale.

Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer patient assistance programs for uninsured or underinsured patients. These programs can significantly reduce out-of-pocket costs for eligible patients.

When counseling patients about compounded vs. branded GLP-1s, be transparent:

What to say:

• "Compounded semaglutide uses the same active ingredient as Wegovy, but it's prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk."
• "The clinical trials that showed cardiovascular benefits were done with the branded product. We don't have the same long-term data for compounded preparations."
• "Compounded preparations are significantly less expensive and don't require insurance prior authorization."
• "I recommend compounded preparations for patients who cannot access or afford the branded product."

What to document:

• The reason for prescribing a compounded preparation (cost, access, specific formulation need)
• The patient's understanding that the preparation is compounded and not FDA-approved
• Informed consent

The coverage gap for GLP-1 medications has become a significant policy issue. Several developments to watch:

Medicare coverage expansion: Legislation to expand Medicare coverage for GLP-1s for obesity has been introduced but not yet passed. If enacted, this would dramatically expand access for Medicare beneficiaries.

Employer coverage trends: Large employers are increasingly adding GLP-1 coverage, but with cost management measures (prior authorization, step therapy, quantity limits).

State Medicaid expansion: Some states are expanding Medicaid coverage for GLP-1s. This is a state-by-state development to monitor.

Request portal access →

This content is for informational purposes only. Insurance coverage information is subject to change. Verify current coverage with individual payers.